SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : qtrn(quintiles trans)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rich Doherty who wrote (4)3/7/1998 3:01:00 PM
From: DTselentis  Read Replies (2) of 105
 
With the earnings projections for CRO's -- Quintiles included for the next few years this stock should continue to do well. While it is highly valued--- its #1 in its industry segment.
The trend for outsourcing is strong within the pharmacetical industry and should expand even further in the future. In addition, the biotech industry is experiencing a dramatic increase in the number of drug candidates that need to be tested in clinical trials. These trends should help companies like Quintiles grow at a good clip for years to come.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News